| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | NEUTRAL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.37▼ | 3.37▼ | 3.37▼ | 3.36▼ | 3.08▲ |
| MA10 | 3.37▼ | 3.38▼ | 3.40▼ | 3.36▼ | 3.35▼ |
| MA20 | 3.37▼ | 3.40▼ | 3.38▼ | 3.11▲ | 3.54▼ |
| MA50 | 3.38▼ | 3.34▼ | 3.39▼ | 3.37▼ | N/A |
| MA100 | 3.40▼ | 3.39▼ | 3.24▲ | 3.47▼ | N/A |
| MA200 | 3.37▼ | 3.20▲ | 3.14▲ | 2.90▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▼ | -0.008▼ | -0.004▼ | 0.051▲ | -0.124▼ |
| RSI | 38.418▼ | 44.627▼ | 46.901▼ | 52.449▲ | 51.338▲ |
| STOCH | 64.286 | 25.684 | 32.965 | 63.273 | 32.127 |
| WILL %R | -100.000▼ | -100.000▼ | -62.500 | -34.444 | -55.932 |
| CCI | -163.624▼ | -103.942▼ | -42.912 | 51.586 | -25.425 |
|
Tuesday, April 29, 2025 05:02 AM
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl ...
|
|
Tuesday, April 29, 2025 05:00 AM
Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/05/25 | 3.49 | 3.498 | 3.34 | 3.34 | 1,042,900 |
| 30/04/25 | 3.35 | 3.49 | 3.255 | 3.47 | 744,428 |
| 29/04/25 | 3.28 | 3.435 | 3.19 | 3.37 | 995,789 |
| 28/04/25 | 3.43 | 3.54 | 3.195 | 3.27 | 1,561,301 |
| 25/04/25 | 3.47 | 3.47 | 3.29 | 3.35 | 624,071 |
| 24/04/25 | 3.51 | 3.54 | 3.35 | 3.45 | 914,900 |
| 23/04/25 | 3.58 | 3.60 | 3.45 | 3.52 | 1,394,795 |
| 22/04/25 | 3.33 | 3.65 | 3.33 | 3.47 | 1,239,400 |
| 21/04/25 | 3.07 | 3.33 | 3.05 | 3.28 | 1,531,700 |
| 17/04/25 | 3.00 | 3.14 | 2.97 | 3.10 | 801,700 |
|
|
||||
|
|
||||
|
|